TABLE II -.
The treatment of CKD-aP within 1 year before and after the index date
| CKD-aP-related treatments | –365 days | +365 days | ||||
|---|---|---|---|---|---|---|
| Patients; % on CKD-aP cohort (n = 218) | Mean no of packages per patient treated | Mean DDD per patient treated | Patients; % on CKD-aP cohort (n = 218) | Mean no of packages per patient treated | Mean DDD per patient treated | |
| Differences between drug dispensations within 365 days before and after the index date were not significant (p-value >0.05) through a chi-square test. | ||||||
| CKD-aP = chronic kidney disease-associated pruritus; DDD = defined daily dose; NA = not available. | ||||||
| Gabapentin | 23; 10.6 | 4.7 | 21.0 | 20; 9.2 | 5.4 | 25.5 |
| Antihistamines | 108; 49.5 | 4.6 | 93.6 | 122; 56.0 | 4.2 | 88.2 |
| Ultraviolet light therapy | 3; 1.4 | 2.0 | NA | 3; 1.4 | 4.0 | NA |
| At least one CKD-aP-related treatment | 127; 58.3 | 142; 65.1 | ||||